Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
The Biotech Launch Algorithm: How Multi-Agent AI Is Rewriting Drug Commercialization

The Biotech Launch Algorithm: How Multi-Agent AI Is Rewriting Drug Commercialization

Misra, Mayank

Paperback

Business GeneralManagementGeneral Computers

ISBN13: 9798250272247
Publisher: Independently Published
Published: Mar 1 2026
Pages: 292
Weight: 0.87
Height: 0.61 Width: 6.00 Depth: 9.00
Language: English
Every month a drug launch is delayed costs a blockbuster $40-80 million in forgone revenue.

The industry knows this. And yet the same pattern repeats, launch after launch -- a frantic scramble in the final 90 days before approval to do 18 months of work, leaving commercial teams underprepared, inconsistent, and slower than the market demands.

The Biotech Launch Algorithm is the manual for building a better system.

Pharmaceutical commercialization strategist Mayank Misra spent 15 years running launches the traditional way before building CoPilot -- a multi-agent AI system that generates complete commercial launch plans in hours rather than months, with consistency enforcement that eliminates the cross-functional contradictions that plague launch planning.

This book demonstrates what's possible. Part I diagnoses the structural failure in traditional launch preparation. Part II describes the architecture of a multi-agent commercial AI -- 13 specialized agents working in concert across market intelligence, brand strategy, medical affairs, market access, and regulatory review. Part III walks through a complete, real-world launch plan for atacicept in IgA Nephropathy -- seven full deliverables, produced at a compute cost of $1.20, with honest analysis of what AI gets right and where human expertise remains essential.

Part IV asks: what comes next?

For pharmaceutical commercial leaders, biotech executives, business development professionals, consultants, and investors navigating the AI transformation of drug commercialization -- this is the evidence, the framework, and the roadmap.

The copilot model isn't coming. It's here.

Also in

Business General

View All